This activity is supported by an educational grant from: Argenx

Marinos Dalakas, MD - (Bio)

Advances of Immunotherapies in Autoimmune Neuromuscular Diseases: Targeting B cells, Complement and FcRn
Target-specific agents against B cells, complement and FcRn are promising in treating antibody-mediated neuromuscular diseases, even ensuring long-lasting remissions and excellent tolerance. The mechanism of action of these agents and potential biomarkers of response to therapies useful for the practicing neurologists, will be addressed.
1 AMA PRA Category 1 Credit ™
Norman Latov, MD, PhD - (Bio)

Autoimmune Motor Neuropathies; Acute Motor Axonal Neuropathy and Multifocal Motor Neuropathy
The autoimmune motor neuropathies include Acute Motor Axonal Neuropathy (AMAN) and Multifocal Motor Neuropathy. This course will review the clinical presentation, differential diagnosis, laboratory evaluation, pathogenesis, and treatment of these motor syndromes.

1 AMA PRA Category 1 Credit ™
James F Howard Jr., MD - (Bio)

Targeting the Neuromuscular Junction in Myasthenia Gravis: A Rationale Approach to Treatment.
This course will highlight emerging therapeutics for the treatment of Myasthenia Gravis, an immune mediated chronic disorder of neuromuscular transmission. Multiple limitations to current treatment strategies exist due to persistent disease burden with treatment and the associated treatment burden experienced by the patient. This talk will highlight two rapidly emerging treatments focusing on the inhibition of the neonatal Fc receptor (FcRn) and Complement protein C5 as potential strategies for the treatment of this disease.
1 AMA PRA Category 1 Credit ™
REGISTER
LOGIN